4 December 2024
AstraZeneca appoints Iskra
Reic as Executive Vice President, International
AstraZeneca today announced the
appointment of Iskra Reic as Executive Vice President (EVP),
International with responsibility for overall strategy and driving
sustainable growth across this broad region. This encompasses
China, Asian and Eurasian markets, Middle East & Africa, Latin
America, Australia & New Zealand.
Having joined the Company in 2001,
Iskra has held leadership positions across Central & Eastern
Europe, Eurasia, Middle East & Africa. She was appointed EVP
for Europe & Canada in 2017 and joined AstraZeneca's Senior
Executive Team. Most recently, Iskra launched the Company's
Vaccines and Immune Therapies unit, successfully establishing it at
the forefront of a new and exciting era of disease prevention. In
this role, she was responsible for the early and late-stage
development of the pipeline and portfolio, including COVID-19 and
RSV vaccines and monoclonal antibodies, strategic partnerships and
acquisitions, medical affairs and commercial operations.
Pascal Soriot, CEO, said: "Iskra is
a highly accomplished leader with extensive international
experience across multiple disciplines and a track record of
improving patient access to our innovative and life-changing
medicines. Her experience building partnerships will be invaluable
in taking the fast-growing International region
forward."
Iskra Reic, Executive Vice
President, International, said: "It is a privilege to lead this
broad, diverse and innovative region as we deliver the next wave of
science and innovative medicines. I look forward to working with
our partners, stakeholders and colleagues to improve the lives of
millions of people around the world with our leading medicines and
vaccines."
Iskra succeeds Leon Wang who is on
extended leave from the Company while under investigation in
China.
Biography of
Iskra Reic
Iskra Reic joined AstraZeneca in 2001 and has
since held numerous leadership positions within the Company,
including as Executive Vice-President (EVP) for Europe & Canada
and, since 2021, as EVP, Vaccines & Immune Therapies. She has
also held senior roles across Central & Eastern Europe,
Eurasia, Middle East and Africa. Iskra has served on AstraZeneca's
Senior Executive Team since 2017.
As EVP, Vaccines & Immune Therapies, Iskra
was responsible for both the early and late-stage development of
the Unit's pipeline and portfolio, including COVID-19
and RSV vaccines and monoclonal antibodies, strategic partnerships
and acquisitions, medical affairs and commercial
operations.
Iskra has a PhD and an MBA in Business and
Leadership from the IEDC-Bled School of Management, Slovenia. She
also holds a DMD from the Medical University of Zagreb. She is a
member of the Board of Directors of myTomorrows, a global health
technology company, and Steering Committee of the Partnership for
Health System Sustainability and Resilience, a global collaboration
dedicated to improving patient outcomes.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and follow
the Company on social media @AstraZeneca
Adrian Kemp
Company Secretary
AstraZeneca PLC